Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 2/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 13/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20334567 | 0.83 | CHRNB2 (0.36) | OPRL1CYP17A1CYP11B2HIPK2 | |
| SCHEMBL526318 | 0.74 | OPRL1 (0.37) | OPRL1CYP17A1RPS6KA3CYP11B2HIPK2 | |
| SCHEMBL29517316 | 0.74 | AOC1 (0.42) | OPRL1CYP17A1 | |
| SCHEMBL793757 | 0.74 | AOC1 (0.42) | OPRL1CYP17A1 | |
| SCHEMBL16132536 | 0.74 | OPRL1 (0.57) | OPRL1CYP17A1 | |
| SCHEMBL29410681 | 0.74 | RPS6KA3 (0.42) | OPRL1CYP17A1RPS6KA3HIPK2 | |
| Ammonia Solution, Strong SCHEMBL22749582 | 0.72 | AOC1 (0.41) | OPRL1CYP17A1 | |
| Hydrochloric Acid SCHEMBL9953248 | 0.72 | AOC1 (0.44) | OPRL1CYP17A1 | |
| SCHEMBL10716565 | 0.71 | CHRNB2 (0.37) | OPRL1CYP17A1RPS6KA3CYP11B2 | |
| SCHEMBL27285547 | 0.71 | CA12 (0.41) | OPRL1CYP17A1RPS6KA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021063346-A1 | KRAS G12C INHIBITOR AND APPLICATION THEREOF | 上海迪诺医药科技有限公司 | 2021-04-08 | — | — | WO | disclosed |
| EP-2702052-B1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2017-10-18 | — | — | EP | disclosed |
| EP-2702052-B1 | 17ALPHA-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2017-10-18 | — | — | EP | disclosed |
| US-9339501-B2 | 17a-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| US-9339501-B2 | 17a-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| US-9339501-B2 | 17a-hydroxylase/C17,20-lyase inhibitors | NOVARTIS AG (CH) | 2016-05-17 | — | — | US | disclosed |
| CN-103649073-B | 17 α-hydroxylase/C 17,20-lyase inhibitor | NOVARTIS AG (CH) | 2016-04-13 | — | — | CN | disclosed |
| US-20150209356-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150209356-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20150209356-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2015-07-30 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2014-02-13 | — | — | US | disclosed |
| EP-2627648-A1 | 17aHYDROXYLASE/C17,20-LYASE INHIBITORS | Novartis AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| WO-2013084138-A1 | CYCLIC UREA DERIVATIVES AS ANDROGEN RECEPTOR ANTAGONISTS | NOVARTIS AG (CH) | 2013-06-13 | — | — | WO | disclosed |
| CN-103108871-A | 17a-hydroxylase/c17,20-lyase inhibitors | NOVARTIS AG | 2013-05-15 | — | — | CN | disclosed |
| WO-2012149413-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012149413-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2012035078-A1 | 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| WO-2008046216-A1 | KINASE INHIBITORS AND USES THEREOF | METHYLGENE, INC. (CA) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209356-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | OPRL1 2818/4885CYP17A1 1/4885RPS6KA3 2332/4885 |
| US-20140045872-A1 | 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS | CYP17A1, CYP21A2, HSD17B1 | OPRL1 2665/4885CYP17A1 1/4885RPS6KA3 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.